Community hub
0 subscribers8 pages, 0 posts
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to Proxalutamide.
Nothing was collected or created yet.
Proxalutamide
View on Wikipediafrom Wikipedia
 | |
| Clinical data | |
|---|---|
| Other names | Pruxelutamide; GT-0918 |
| Routes of administration | By mouth |
| Drug class | Nonsteroidal antiandrogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H19F4N5O2S |
| Molar mass | 517.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer.[1][2][3][4][5] It was approved in Paraguay for the treatment of COVID-19 in July 2021, but has not been approved at this time in other countries.[1]
Research
[edit]Prostate cancer
[edit]Proxalutamide is in phase III studies for mCRPC as monotherapy and in combination with abiraterone. In the United States, it is in phase II study as monotherapy for mCRPC.[6][7]
Other indications
[edit]See also
[edit]References
[edit]- ^ a b c "Proxalutamide - Suzhou Kintor Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ Tong Y, Chen C, Wu J, Yang J, Zhang H, Wu X, et al. (2014). "Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor". Cancer Research. 74 (19 Supplement): 614. doi:10.1158/1538-7445.AM2014-614. ISSN 0008-5472.
- ^ Tong Y, Chen C, Wu J, Zhang H, Wu X, Duan Y, Gao W, Niu X, Ma L, Guo C (2014). "Discovery of potent androgen receptor antagonists for treating CRPC and AR+ breast cancer". Cancer Research. 73 (8 Supplement): 2460. doi:10.1158/1538-7445.AM2013-2460. ISSN 0008-5472.
- ^ "Anti-Androgen Treatment for COVID-19". ClinicalTrials.gov. 2020-12-29.
- ^ "Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Results in Treatment of Male and Female". Bloomberg.com (Press release). EQS. 2021-01-10. Archived from the original on 2021-03-01. Retrieved 2025-01-09.
- ^ "Product Pipeline". Kintor Pharmaceutical. Archived from the original on 2021-02-03. Retrieved 2021-01-29.
- ^ Suzhou Kintor Pharmaceutical (2020-03-13). "An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide". Clinical Trials. US.
- ^ "Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer". Clinical trials. 24 September 2019. Retrieved 2021-01-29.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information. |